Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| DARENCA STUDY 2 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Copenhagen University Hospital at Herlev | OTHER |
| Rigshospitalet, Denmark | OTHER |
| Aarhus University Hospital | OTHER |
| Odense University Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Non-interventional study. Data obtained by patient chart reviews.
Retrospective analysis of progression free survival, time to treatment failure and overall survival in a national cohort of patients with metastatic renal cell carcinoma treated in Denmark from 2006-2010 Safety, prognostic factors, predictive factors and co-morbidity assessed by Charlson Comorbidity Index.
The following drugs will be evaluated: Sunitinib, Sorafenib, Temsirolimus, Everolimus, Aldesleukin, Interferon-alfa-2b.
No sampling. All eligible patients will be included.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-Interventional Study | Outcomes Research Study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-interventional | Other | Non-interventional (retrospective chart reviews) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival from initiation of first systemic anticancer therapy | 8 months | |
| Progression free survival from initiation of each systemic anticancer therapy separately | 8 months | |
| Time to treatment failure from initiation of each systemic anticancer therapy separately | 8 months |
| Measure | Description | Time Frame |
|---|---|---|
| Prognostic factors at baseline associated with efficacy (PFS) of each systemic anticancer therapy and overall survival | 8 months | |
| Serious Adverse Events: Defined as AEs leading to dose adjustment, treatment interruption/ cessation or death. | 8 months |
Not provided
Inclusion Criteria:
Metastatic renal cell carcinoma
Exclusion Criteria:
None
Not provided
Not provided
Not provided
All Danish patients diagnosed with metastatic renal cell carcinoma referred to the involved centers.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Copenhagen Herlev Hospital | Herlev | 2730 | Denmark |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
| OTHER |
| Danish Renal Cancer Study Group | NETWORK |
Not provided
Not provided
Not provided
| Predictive factors | 8 months |
| Co-morbidity assessed by Charlson Comorbidity Index | 8 months |
| Combined PFS and OS on sequential treatment | 8 months |
| Assessment of first line immunotherapy´s effect on second line targeted therapy | 8 months |
| Assessment of prognostic factors and overall survival for patients not receiving systemic therapy | 8 months |
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided